|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We analyzed data from a cohort of 161 patients to determine whether there were any racial differences in PSA levels prior to treatment in local-regional prostate cancer.
|
1284591 |
1993 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We analyzed data from a cohort of 161 patients to determine whether there were any racial differences in PSA levels prior to treatment in local-regional prostate cancer.
|
1284591 |
1993 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, our results are not unequivocal, but our data do suggest that racial differences in PSA levels not accounted for by tumor stage or grade may exist.
|
1284591 |
1993 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
When LNCaP tumors were grown in castrated male hosts, levels of c-erb B-2/neu and PSA mRNA expression decreased initially, but rebounded at 3 wk to levels comparable to those expressed by tumors maintained in intact adult male hosts.
|
1353965 |
1992 |
|
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen (PSA) has emerged as the most useful marker for management of patients with prostate cancer.
|
1379363 |
1992 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen (PSA) has emerged as the most useful marker for management of patients with prostate cancer.
|
1379363 |
1992 |
|
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The current work reports a detailed study of PSA glycoprotein expression as influenced by steroid hormones in a human prostatic adenocarcinoma cell line, LNCaP.
|
1379363 |
1992 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma.
|
1380992 |
1992 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
No significant differences could be found in the PSA gene expression between BPH and CA samples.
|
1691151 |
1990 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No significant differences could be found in the PSA gene expression between BPH and CA samples.
|
1691151 |
1990 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate.
|
1691151 |
1990 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Many of the tumor specimens showed a heterogeneous expression of PSA, whereas all of the benign epithelium had a uniform high level of PSA expression.
|
1700164 |
1990 |
|
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer.
|
1710533 |
1991 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Both PSA and DNA ploidy analysis by flow cytometry appear to be valuable indicators in the evaluation of patients with prostatic carcinoma.
|
1710533 |
1991 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mean PSA values were higher in patients with aneuploid tumors (P = 0.078), extraprostatic neoplasms (P = 0.00001), and cancers with a Gleason score of 6 to 10 (P = 0.0004).
|
1710533 |
1991 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mean PSA values were higher in patients with aneuploid tumors (P = 0.078), extraprostatic neoplasms (P = 0.00001), and cancers with a Gleason score of 6 to 10 (P = 0.0004).
|
1710533 |
1991 |
|
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
PSA protein has been an important biological marker for prostate cancers.
|
1712248 |
1991 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of prostate-specific antigen (PA) mRNA was tested at various time periods after incubation of the human prostate tumor cell line LNCaP with the synthetic androgen R1881.
|
1724287 |
1991 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Outcome was predicted correctly by random sampled absolute (17 of 18 cases) and relative (16 of 18) nuclear roundness factor (NRF), tumor volume expressed as percent of specimen (13 of 16), primary (13 of 18), secondary (14 of 18), sum (15 of 18), and worse (14 of 18) Gleason grades and prostate-specific antigen immunohistochemical findings (13 of 18) that produced statistically significant separation of the two groups.
|
1728382 |
1992 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical stage A2 cancer was associated with a significantly higher progression rate (when prostate specific antigen values were considered, p = 0.0011) and cancer death rate (p less than 0.045) than stage A1 disease, whereas pathological stage was not significantly related to disease outcome, possibly because of the use of adjuvant treatment (hormonal or radiation) for some patients with pathological stage C or higher disease.
|
1895421 |
1991 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical stage A2 cancer was associated with a significantly higher progression rate (when prostate specific antigen values were considered, p = 0.0011) and cancer death rate (p less than 0.045) than stage A1 disease, whereas pathological stage was not significantly related to disease outcome, possibly because of the use of adjuvant treatment (hormonal or radiation) for some patients with pathological stage C or higher disease.
|
1895421 |
1991 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumors grown in nude mice revealed a poorly differentiated adenocarcinoma with positive PSA staining.
|
2195744 |
1990 |
|
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
The close resemblance of prostate specific antigen, a marker for prostatic cancer, to glandular kallikrein suggests related immunogenic properties for them.
|
2470373 |
1989 |
|
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Currently, the TNM (Tumor, Lymph Node, Metastasis) staging system, histologic grading (Gleason system), and serum prostate-specific antigen are recommended for general use as prognostic markers in prostate cancer.
|
7503660 |
1995 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Currently, the TNM (Tumor, Lymph Node, Metastasis) staging system, histologic grading (Gleason system), and serum prostate-specific antigen are recommended for general use as prognostic markers in prostate cancer.
|
7503660 |
1995 |